Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy for Detection of Early Alzheimer’s Disease

Eric Westmanb,c, Lars-Olof Wahlanda, Catherine Foyb, Michaela Poppeb, Allison Cooperb, Declan Murphyb, Christian Spengerd, Simon Lovestoneb and Andrew Simmonsb,c

aDepartment of Neurobiology, Care Sciences and Society, Section of Clinical Geriatrics, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
bNIHR Specialist Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and King’s College London and the MRC Centre for Neurodegeneration, Kings College London, Institute of Psychiatry, London, UK
cDepartment of Neuroimaging, Kings College London, Institute of Psychiatry, London, UK
dDepartment of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden

Abstract. Alzheimer’s disease is the most common form of neurodegenerative disorder and early detection is of great importance if new therapies are to be effectively administered. We have investigated whether the discrimination between early Alzheimer’s disease (AD) and elderly healthy control subjects can be improved by adding magnetic resonance spectroscopy (MRS) measures to magnetic resonance imaging (MRI) measures.

In this study 30 AD patients and 36 control subjects were included. High resolution T1-weighted axial magnetic resonance images were obtained from each subject. Automated regional volume segmentation and cortical thickness measures were determined for the images. 1H MRS was acquired from the hippocampus and LCModel was used for metabolic quantification. Altogether, this yielded 58 different volumetric, cortical thickness and metabolite ratio variables which were used for multivariate analysis to distinguish between subjects with AD and Healthy controls. Combining MRI and MRS measures resulted in a sensitivity of 97% and a specificity of 94% compared to using MRI or MRS measures alone (sensitivity: 87%, 76%, specificity: 86%, 83% respectively). Adding the MRS measures to the MRI measures more than doubled the positive likelihood ratio from 6 to 17.

Adding MRS measures to a multivariate analysis of MRI measures resulted in significantly better classification than using MRI measures alone. The method shows strong potential for discriminating between Alzheimer’s disease and controls.

Keywords: MRS, MRI, OPLS, AD, multivariate analysis

INTRODUCTION

Multivariate analysis provides the opportunity to analyze many variables simultaneously and observe inherent patterns in the data. Methods like principal component analysis (PCA), Partial least square to latent structures (PLS) and orthogonal PLS (OPLS) are efficient, robust and validated tools for modelling complex biological data [1].

Alzheimer’s disease (AD) is one of the most common forms of neurodegenerative disorders. The clinical symptoms of AD include gradual loss of cognitive functions and AD is largely a disorder of the
elderly with a small percentage of non-age-related AD cases being familial and secondary to specific gene mutations.

Magnetic resonance imaging (MRI) is a non-invasive method which has been widely studied for early detection and diagnosis of AD [2–4]. In particular early changes in hippocampus and entorhinal cortex have been demonstrated using MRI [5–9]. These early changes are consistent with the underlying pathology of AD but it is not yet clear which measures are most useful for early diagnosis [2]. Due to the complexity of this disorder measures of single structures from MRI are probably not sufficient for accurate diagnosis at the early stages of the disease. The most common way of describing the spread of atrophy in AD is according to the neurofibrillary tangle spread described by Braak and Braak [10]. It has also been proposed that the pattern of atrophy can progress in other ways, where the hippocampus and entorhinal cortex are not as affected [11]. By combining different measures of atrophy using multivariate methods we might gain a better understanding of the natural history of the disease.

Magnetic resonance spectroscopy (1H-MRS) provides useful information on the neurochemical profile of different neurodegenerative diseases [12, 13] from defined target volumes in vivo. The metabolites measured represent different aspects of the pathological processes in AD [13]. Examples of measurable metabolites are N-acetylaspartate (NAA), a marker for neuronal density and/or function, myo-inositol (mI), a marker for astroglialosis and/or osmotic stress and choline (Cho), a marker for cell membrane turnover and degradation [14]. Brain metabolites are sensitive to pathological processes in neurodegenerative disorders such as AD [13].

Other MR modalities which can be used for the study of AD include diffusion MRI which measures microstructural changes in white matter [15], functional MRI which measures brain function using BOLD contrast [16], arterial spin labelling which measures the perfusion of blood [17] and MR-relaxometry which characterizes T1 and T2 relaxation times of tissue [18].

McEvoy et al. have previously shown with a largely automated image analysis pipeline that using multiple MRI measurements of regional volumes and regional cortical surface measurements in combination with multivariate analysis is useful in distinguishing between subjects with Alzheimer’s disease and healthy controls [19]. This indicates that a combination of different MRI measures may prove to be more useful than hippocampal or entorhinal cortex measures alone for early detection of Alzheimer’s disease. The use of automated measures may in particular have advantages when it comes to widespread uptake in either clinical or research practice. Several other studies have utilized different multivariate techniques including OPLS to analyze MR-data [20–26]. Alzheimer’s disease is a complex disorder and one biomarker is probably not enough to establish a correct diagnosis. Therefore we wanted to investigate the potential of combining different MRI measures (i.e. regional volumes and regional cortical thickness measures) with MRS measures. OPLS was chosen to analyze the large number of variables generated from the different MR-modalities. The aim of this study was to investigate whether adding MRS measures to a battery of automated structural MRI measures would further improve the ability to distinguish patients with AD from healthy controls using multivariate data analysis.

**MATERIAL AND METHODS**

**Study data and inclusion and diagnostic criteria**

Thirty patients with Alzheimer’s disease and 36 healthy volunteers were included in this study who had both MRI and hippocampal MRS. Table 1 gives the demographics of the study cohort. The study population was derived from a largely community-based population of subjects with AD and healthy elderly people [Alzheimer’s Research Trust (ART) cohort] [27]. Community or nursing home resident cases with NINCDS-ADRDA (The National Institute of Neurological and Communicative Disorders and Stroke - the Alzheimer’s disease and related Disorders Association) probable-AD were identified from secondary care.

<table>
<thead>
<tr>
<th>Variable</th>
<th>AD</th>
<th>CONTROL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>30</td>
<td>36</td>
</tr>
<tr>
<td>Gender (female/male)</td>
<td>15/15</td>
<td>22/14</td>
</tr>
<tr>
<td>Mean age (SD)</td>
<td>77.3 (5.0)</td>
<td>76.5 (5.1)</td>
</tr>
<tr>
<td>Mean MMSE (SD)</td>
<td>23.1 (3.6)</td>
<td>29.4 (0.7)</td>
</tr>
<tr>
<td>Mean GDS (SD)</td>
<td>4.0 (0.7)</td>
<td>–</td>
</tr>
<tr>
<td>Mean duration of disease (years; SD)</td>
<td>4.3 (2.3)</td>
<td>–</td>
</tr>
<tr>
<td>Mean years of education (years; SD)</td>
<td>11.2 (3.1)</td>
<td>11.7 (3.2)</td>
</tr>
</tbody>
</table>

Data are represented as average ± standard deviation. AD = Alzheimer’s Disease, CONTROL = healthy controls, MMSE = Mini Mental State Examination and GDS = Global Dementia Scale.
services for elderly people with dementia. In addition to a clinical diagnosis, subjects were assessed with a standardised assessment protocol including informant interview for diagnosis, MMSE and Global Dementia Scale (GDS) assessments for severity. Healthy volunteers were recruited from non-related members of the patient’s families, caregiver’s relatives or social centres for the elderly. The inclusion and exclusion criteria were as follows.

Alzheimer’s disease

**Inclusion criteria:** (1) ADRDA/NINCDS and DSM-IV criteria for probable Alzheimer’s disease. (2) Mini Mental State Examination score range between 12 and 28. (3) Age 65 years or above.

**Exclusion criteria:** (1) Significant neurological or psychiatric illness other than Alzheimer’s disease. (2) Significant unstable systematic illness or organ failure.

Controls

**Inclusion criteria:** (1) Mini Mental State Examination score >26. (2) Geriatric Depression Scale score less than or equal to 5. (3) Age 65 years or above. (4) Medication stable. (5) Good general health.

**Exclusion criteria:** (1) Meet the DSM-IV criteria for Dementia. (2) Significant neurological or psychiatric illness other than Alzheimer’s disease. (3) Significant unstable systematic illness or organ failure.

Although additional subjects had MRI only the cohort considered here did not differ statistically from the larger cohort. MRI and MRS measures were not a part of the clinical evaluation and therefore did not influence the diagnostic decision. This study was approved by the South London and Maudsley NHS Trust research ethics committee.

**MRI and MRS acquisition**

Subjects were scanned using a 1.5 Tesla, GE NV/i Signa MR system (General Electric, Milwaukee, WI, USA) at the Maudsley Hospital, London. 3D T1-weighted volume images were acquired in the axial plane with 1.5-mm contiguous sections using acquisition parameters chosen using a contrast simulation tool [28]. Repetition time (TR) was 13.8 ms, inversion time (TI) 450 ms, echo time (TE) 2.8 ms, and the flip angle was 20° with one data average and a 256 × 256 × 124 voxel matrix. Acquisition time was 6 min, 27 s. 1H-MRS voxels of interest measuring 20 × 20 × 15 mm³ (6 mL) were defined in standard locations in the left and right hippocampus using previously published methods [29]. We chose hippocampal regions of interest as this is one of the earliest sites of change in Alzheimer’s disease. The anterior extent of the voxel was defined as the coronal slice where the amygdala disappeared, with the posterior extent 20 mm from this (Fig. 1A). The hippocampal volume of interest contained both grey and white matter and included the parahippocampal gyrus and the posterior portion of the amygdala. A point resolved spectroscopy (PRESS) pulse sequence (TE 35 ms, TR 1500 ms, 256 data averages and 2048 points) with automated shimming and water suppression and excellent reproducibility [30] was used to obtain spectra from each voxel after CHESS water suppression with high signal to noise ratio and clearly resolved NAA, Cho, m and Cr + PCr peaks among other metabolites. Not all subjects had spectral data from both left and right hippocampus. No significant differences were found in the metabolic content between the right and the left side of hippocampus. Therefore, we averaged the metabolic ratios from the left and right hippocampus from the subjects which had data from both hemispheres.

**MRI data analysis**

Freesurfer (version 5.0.0), a highly automated structural MRI image processing pipeline was utilised for data analysis. The pipeline produces regional cortical thickness and volumetric measures. Cortical reconstruction and volumetric segmentation includes removal of non-brain tissue using a hybrid watershed/surface deformation procedure [31], automated Talairach transformation, segmentation of the subcortical white matter and deep grey matter volumetric structures including hippocampus, amygdala, caudate, putamen, ventricles [31–33] intensity normalization [34], tessellation of the grey matter white matter boundary, automated topology correction [35, 36], and surface deformation following intensity gradients to optimally place the grey/white and grey/cerebrospinal fluid borders at the location where the greatest shift in intensity defines the transition to the other tissue class [37–39]. Once the cortical models are complete, registration to a spherical atlas takes place which utilizes individual cortical folding patterns to match cortical geometry across subjects [40]. This is followed by parcellation of the cerebral
cortex into units based on gyrual and sulcal structure [41, 42]. Fig. 2A and B show representations of ROIs included as candidate input variables in the multivariate OPLS model. All volumetric measures from each subject were normalized by the subject’s intracranial volume. This segmentation approach has previously been used for neuropsychological-image analysis [43, 44], imaging-genetic analysis [45–47] and biomarker discovery [48, 49].

MRS data analysis

The software package LCModel (http://www.s-provencher.com) [50, 51] was used for the analysis of the spectra. Fig. 1B shows a representative LCModel output, a spectrum with the model fit. The LCModel algorithm applies linear combinations of individual metabolite signals to calculate the best fit of the experimental spectra to the model spectra. In this case, a basis set of alanine, aspartate, creatine, gamma-aminobutyric acid (GABA), glutamine, glutamate, glycerophosphocholine, ml, lactate, NAA, N-acetyl-aspartylglutamate (NAAg), scyllo-inositol, and taurine, together with a baseline function were used for analysis. As expected, many of the metabolite peaks included in the LC-model did not reach statistical significance for all spectra. Metabolite concentration ratios relative to creatine + phosphocreatine (Cr + PCr) were calculated as applied by others [52, 53]. To ensure that differences in tissue composition did not account for metabolite differences between subject groups, we segmented the 3-D T1 weighted volume using SPM (Statistical Parametric Mapping) software (http://www.fil.ion.ucl.ac.uk/spm) to determine the percentage of grey and white matter and CSF composition within each MRS voxel. The metabolite concentrations reported by LCModel were divided by the fractional content of brain tissue (p[GM] + p[WM], where p[GM] and p[WM] represent the percentage of grey matter and white matter in the voxel, respectively) to correct for the relative proportion of cerebrospinal fluid (CSF) in the MRS voxel (mean(SD) for AD = 0.10(0.04) and for controls = 0.16(0.07), p = 7.2e-6). The fraction p[GM] was calculated for each subject to investigate if there were any significant differences in gray content between AD patients and control subjects in the MRS voxels. No significant differences were observed (mean(SD) for AD = 0.62(0.07) and for controls = 0.65(0.06), p = 0.60). The metabolite ratios included in the study were: myo-inositol (ml/Cr + PCr), choline-containing compounds (Cho/Cr + PCr) and N-acetylaspartate + N-acetylaspartylglutamate (NAA + NAAg/Cr + PCr).
Multivariate data analysis

MRI measures were analyzed using orthogonal partial least squares to latent structures (OPLS) [1, 24, 54–56], a supervised multivariate data analysis method included in the software package SIMCA (Umetrics AB, Umea, Sweden). A very similar method, partial least squares to latent structures (PLS) has previously been used in several studies to analyze MR-data [23, 25, 26, 57, 58]. OPLS and PLS are very similar methods and when performed, give the same predictive accuracy. The advantage of OPLS compared to PLS is that the model created to compare groups is rotated. This means that the information related to class separation is found in the first component of the model, the predictive component. The other orthogonal components in the model, if any, relate to variation in the data not connected to class separation. Focusing the information related to class separation on the first component makes data interpretation easier [1]. Pre-processing was performed using mean centring and unit variance scaling. Mean centring improves the interpretability of the data, by subtracting the variable average from the data. By doing so the data set is repositioned around the origin. Large variance variables are more likely to be expressed in modeling than low variance variables. Consequently, unit variance scaling was selected to scale the data appropriately. This scaling method calculates the standard deviation of each variable. The inverse standard deviation is used as a scaling weight for each MR-measure.

The results from the OPLS analysis are visualized in a scatter plot by plotting the predictive component, which contains the information related to class separation. Components are vectors, which are linear combinations of partial vectors and are dominated by the input variables (x). The first and second components are by definition orthogonal to each other and span the projection plane of the points. Each point in the scatter plot represents one individual subject.
The predictive component receives a $Q^2(Y)$ value that describes its statistical significance for separating groups. $Q^2(Y)$ values $>0.05$ are regarded as statistically significant and a model with a $Q^2(Y)$ value $>0.5$ is regarded as good [59].

$$Q^2(Y) = 1 - \frac{PRESS}{SSY}$$

PRESS (predictive residual sum of squares) = $\Sigma y_{actual} - y_{predicted}^2$ and SSY is the total variation of the Y matrix after scaling and mean centring [59]. $Q^2(Y)$ is the fraction of the total variation of the Ys (expected class values) that can be predicted by a component according to cross validation (CV). Cross validation is a statistical method for validating a predictive model which involves building a number of parallel models. These models differ from each other by leaving out a part of the data set each time. The data omitted is then predicted by the respective model. In this study we used seven fold cross-validation, which means that 1/7th of the data is omitted for each cross-validation round. Data is omitted once and only once. Variables were plotted according to their importance for the separation of groups. The plot shows the MRI measures and their corresponding jack-knifed confidence intervals. Jack-knifing is used to estimate the bias and standard error. Measures with confidence intervals that include zero have low reliability [1].

Covariance is plotted on the y-axis.

$$\text{Cov}(t, X_i) = \frac{t^TX_i}{(N - 1)}$$

Where $t$ is the transpose of the score vector $t$ in the OPLS model, $i$ is the centered variable in the data matrix $X$ and $N$ is the number of variables [1]. A measure with high covariance is more likely to have an impact on group separation than a variable with low covariance. MRI and MRS measures below zero in the scatter plot have lower values in controls compared to AD subjects, while MRI and MRS measures above zero are higher in controls compared to AD subjects in the model.

Altogether 58 variables were used for OPLS analysis. No feature selection was performed, meaning all measured variables were included in the analysis. Three OPLS models were created. The first model contained MRS measures, the second model contained MRI measures and the third model combined both MRI and MRS measures. OPLS has previously been used to combine measures from different techniques [54, 56]. Models containing age, gender and education were also created to test if there were any significant differences between the groups in these measures. Finally we also investigated whether age, gender and education would increase the predictive power of the models using them as x-variables. As the models demonstrated no effect of age, gender and education these were excluded from further analysis.

The sensitivity and the specificity were calculated from the cross-validated prediction values received from the OPLS models. Finally, the positive likelihood ratios ($LR^+ = \text{sensitivity}/(100-\text{specificity})$) were calculated. A positive likelihood ratio between 5-10 increases the diagnostic value in a moderate way, while a value above 10 significantly increases the diagnostic value of the test [60].

RESULTS

Subject cohort

Sixty-six subjects were included in this study: 30 AD patients and 36 controls as detailed in Table 1. The gender distribution was equal for the AD subjects, but there were more females than males within the control group. Neuropsychological test results did not differ between females and males and gender differences were accounted for by dividing each regional volume by the subjects’ intracranial volume. There were no significant differences between the two groups regarding age and education. As expected, the mean MMSE scores were significantly higher for the control group than the AD group. To measure the disease severity of the AD group the Global Dementia Scale was used. The mean value for the group was 4, which corresponds to mild dementia. Finally the mean disease duration of the AD subjects was 4 years.

OPLS modelling and quality

Three models were created, the first using MRS measures, the second using MRI measures and the third model using both MRI and MRS measures. The first model (MRS measures) resulted in one predictive component. The model accounted for 59% of the variance of the original data ($R^2(X)$) and its' cross validated predictability, $Q^2(Y) = 31\%$. The second model (MRI measures) resulted in one predictive component and one orthogonal component. For this model $R^2(X) = 59\%$ and the cross validated predictability, $Q^2(Y) = 57\%$. The third model (MRI + MRS) resulted in one predictive component and two orthogonal
components, $R^2(X) = 62\%$ and its cross validated predictability, $Q^2(Y) = 67\%$.

**Cross validated scatter plots**

Figure 3A shows the separation between AD and controls using MRS measures. This resulted in a sensitivity of 76\% and specificity of 83\%. In the model containing automated regional volume measures and regional cortical thickness measures a sensitivity of 87\% and a specificity of 86\% was found (Fig. 3B). The third model (MRI + MRS) had the highest prediction accuracy (Fig. 3C) yielding a sensitivity of 97\% and a specificity of 94\%. The positive likelihood ratio more than doubled from 6 to 17 when the MRI and MRS measures were combined (Table 2). This significant improvement in diagnostic accuracy can also be observed in the increase of $Q^2(Y)$ described above.

![Fig. 3. OPLS cross validated score plots (A) MRS measures (B) MRI Measures (C) The combination of MRI and MRS measures. The scatter plots visualize group separation and the predictability of the three different AD vs. controls models. Each grey circle represents an AD subject and each black square a control subject. Control subjects to the left of zero and AD subjects to the right of zero are falsely predicted. $Q^2(Y) > 0.05$ (statistically significant model) and $Q^2(Y) > 0.5$ (good model).]
Table 2
Sensitivity/specificity and positive Likelihood Ratio (LR+)

<table>
<thead>
<tr>
<th>AD vs. CONTROL</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>LR+</th>
<th>Q2(Y)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRS measures</td>
<td>76% (59–88)</td>
<td>83% (71–94)</td>
<td>5 (2–10)</td>
<td>0.31</td>
</tr>
<tr>
<td>MRI measures</td>
<td>87% (70–95)</td>
<td>86% (71–94)</td>
<td>6 (3–14)</td>
<td>0.57</td>
</tr>
<tr>
<td>MRI+MRS measures</td>
<td>97% (83–99)</td>
<td>94% (82–98)</td>
<td>17 (5–67)</td>
<td>0.67</td>
</tr>
</tbody>
</table>

MRI = magnetic resonance imaging, MRS = magnetic resonance spectroscopy, AD = Alzheimer’s disease, CONTROL = healthy controls, LR+ = likelihood ratio = sensitivity/(1-specificity), confidence intervals for the sensitivity, specificity and LR+ within parenthesis, Q2(Y) > 0.05 (statistically significant model), Q2(Y) > 0.5 (good model) and Q2(Y) > 0.7 (excellent model).

Variables responsible for separation

Figure 4 illustrates the importance of the different variables in the model containing both MRI and MRS measures. Medial, lateral temporal lobe structures and isthmus cingulate as well as parietal and orbitofrontal regions were important for the separation between the two groups. The most important spectroscopic measure was NAA/Cr + PCr.

DISCUSSION

Modern technology can allow high resolution MR images to be acquired in relatively short period of time which are suitable for making large numbers of measures from. However it can be more challenging to study large numbers of patients due to cost and time constraints. Classical analysis methods such as multiple linear regression and analysis of variance assume statistical independence between variables and that the variables are highly relevant to the research question in hand [59]. The assumption that variables are statistically independent is not true when the number of variables exceeds the number of observations. Multivariate data analysis methods such as OPLS provide the opportunity to analyze many variables simultaneously. Unlike traditional methods, multivariate projection methods can also handle missing data and are robust to noise in both X and Y [59].

The OPLS method has previously been successfully applied by others to a wide range of data types [1, 54]. Bylesjo et al. have shown that OPLS can be used to combine different types of omics data. They showed that the systematic variation from two analytical platforms could be combined and separated from the systematic variation specific to each analytical platform [54]. This illustrates one of the advantages of OPLS, that it divides the systematic variation within the data set into two parts, one correlated with Y and one uncorrelated with Y, making data interpretation easier [1]. We have also recently used OPLS to analyze data from a large multi-center study (AddNeuroMed) using only structural MRI data as input variables [24].
Model predictability

This study was designed to investigate the feasibility of discriminating between AD and controls using OPLS as a tool combining MRI measures with MRS measures. Several studies have used hippocampal or entorhinal cortex measures for classification between AD and controls with a high degree of accuracy (80%–90%) [5–8, 61–65]. Other prior studies have shown up to 100% accuracy when discriminating between AD and controls but these studies either had very small sample size [66], included more severely impaired AD groups [8, 66, 67] or did not use fully cross-validated results [8, 20, 67, 68]. If cross-validation is not used it can create an optimistic bias in classification accuracy [69, 70]. McEvoy et al. used linear discriminant analysis (LDA) on quantitative structural neuroimaging measures of regional MRI volumes and regional cortical thicknesses to distinguish between Alzheimer’s disease and healthy controls [19]. They obtained a sensitivity of 83%, a specificity of 93% and a positive likelihood ratio of 12 when comparing the two groups. By combining automated regional volumes and cortical thickness measures we found a sensitivity of 87% and specificity of 86% in the current study using the multivariate OPLS technique resulting in a positive likelihood ratio of 6. We found a higher sensitivity but a lower specificity than McEvoy et al. for MRI measures alone which is reflected in the lower positive likelihood ratio. In another study Vemuri et al. used support vector machines (SVM) to classify subjects with probable AD from controls [71]. Including ApoE in their analysis they received a sensitivity of 88%, a specificity of 90% resulting in a positive likelihood ratio of 19. As before, we received a higher sensitivity and a lower specificity. Both the studies described above (Vemuri et al. and McEvoy et al.) are multi centre studies including larger cohorts of subjects, which may be the reason for the lower sensitivity values. Different centres can have slightly different inclusion criteria for AD patients, resulting in a more heterogeneous group. Several other studies have used SVM for discriminating between AD and controls with similar results to ours [21, 22, 72]. PLS, which is a similar method to OPLS, has also been utilized with success for the analysis of MR, PET and MEG data [23, 57].

We compared the discriminant ability of structural MRI analyses with those of MRS and to the combination of MRI and MRS. The model containing only MRS measures gave a sensitivity of 76% and specificity of 83% (LR+ = 5); somewhat less effective in discriminating AD from controls than the structural MRI analyses. The addition of MRS measures to the MRI measures improved the discrimination, however, resulting in a sensitivity of 97% and specificity of 94% which gave a positive likelihood ratio of 17, better than that of McEvoy et al. The sensitivity and specificity of combined measures was greater than either MRI or MRS alone, with a more than doubling of the likelihood ratio. This significant improvement in diagnostic accuracy can also be observed in the increase of $Q^2(Y)$ (Table 2). We have previously also used OPLS to distinguish between AD and controls using another automated pipeline combined with manual hippocampal volumes [24].

The OPLS multivariate method has previously been used to discriminate been groups successfully in other fields of research. Wiklund et al. used gas chromatography coupled mass spectroscopy data to differentiate between two transgenic poplar lines and wild type [1]. Another study combined data from two different platforms (2D-DIEGE proteomic and $^1$H-NMR metabolic data) to analyse blood plasma from mice with a prostate cancer xenograft and matched controls [56]. This study demonstrated that data from different analytical platforms can be successfully combined and gives us a better understanding of in vivo model systems.

MR-measures of importance

McEvoy et al. found that atrophy in medial and lateral temporal, isthmus cingulate and orbitofrontal areas aided the discrimination of control subjects from subjects with AD [19]. We also found that these regions were of importance for the cohort investigated in this study (Fig. 4). This demonstrates that the results can be reproduced and that the automated pipeline analysis methods used in both studies are robust. Decreased levels of NAA/Cr + PCr were observed in AD compared to controls and adding the spectroscopic measures increased the prediction accuracy. Kantarci et al. demonstrated that combining MRI with MRS improves the ability to identify patients with prodromal dementia [73]. Other studies have also shown that the combination of NAA and structural MRI improves the classification accuracy [74, 75]. This indicates the potential value of adding MR spectroscopic measures to volumetric measures in the diagnosis of AD and other neurodegenerative disorders. Metabolic changes have previously been detected in presymptomatic mutation carriers years before expected onset.
which demonstrates the potential use of MRS. It is possible that metabolite ratios provide less information about how individual metabolites change than metabolite concentrations. However, ratios are not susceptible to CSF partial volume effect and may represent more sensitive biomarkers of disease [77]. While we studied hippocampal MRS it would be interesting to apply the same technique to other regions of interest including the anterior cingulate using either single voxel MRS or magnetic resonance spectroscopic imaging (MRSI). A possible explanation for the added value of MRS to MRI is that they reflect different aspects of pathological processes, brain atrophy and metabolic changes. In AD, molecular neuropathology is thought to precede structural brain changes by several years and the neurodegeneration is estimated to start 20–30 years before the clinical diagnosis is given [78]. These factors may play a role in explaining why these methods in combination improve the diagnostic outcome.

Conclusion

Quantitative MRI and MRS measurements in combination can improve the accuracy of discriminating patient with early Alzheimer’s disease from normally cognitive elderly subjects over and above that of MRI measures and multivariate analysis alone. The multivariate method applied here (OPLS) provides the opportunity to analyze all of the MRI and MRS measures simultaneously, allowing the building of robust OPLS models for the prediction of disease characterizing high sensitivity and specificity. Combining the automated MRS measures with MRI measures more than doubled the positive likelihood ratio from 6 to 17 which highlights the importance of MRS measures as a valuable complement to MRI in the diagnosis of Alzheimer’s disease. A potential limitation of the current study is that the analysis technique was applied to a moderately sized MRI study with subjects recruited from a single site. Further, studies are warranted including those focusing on patients with mild cognitive impairment, patients with other types of dementia, longitudinal data and external test data sets to validate the robustness of the models. Applying this approach to typical clinical populations including mixed pathology and unclear clinical presentation would be of particular interest. Ultimately, pathologically confirmed data sets are needed to determine the applicability of the method described. However the improvement in discrimination when adding the MRS measures led to a clear and large improvement in the positive likelihood ratio. We chose a hippocampal region of interest for MRS since this is a particularly relevant area for AD and can be measured in a clinically realistic time. It would be of scientific interest in future to use the same approach described here for MR spectroscopic imaging or multiple single voxel MRS measures, though this may not be realistic for routine clinical imaging. To conclude, combining global and regional measures of atrophy with MRS measures significantly improves the classification accuracy when distinguishing between AD patients and healthy controls. Since all measures can be acquired with fully automated methods it makes them attractive for further use.

ACKNOWLEDGEMENTS

We acknowledge funding from the NIHR Biomedical Research Centre for Mental Health, the Alzheimer’s Research Trust and the EU/EFPIA study, AddNeuroMed. Also thanks to the foundation Gamla Tjänarinnor, the foundation for Ragnar och Einar Lundströmminne, The Swedish Alzheimer’s Association, Swedish Brain Power and Stockholm Medical Image Laboratory and Education (SMILE). There are no actual or potential conflicts of interests.

REFERENCES

hippocampus in diagnosing Alzheimer disease. AJNR Am J Neurosci 20, 139-144.


[29] Dale AM, Sereno MI (1995) Improved localization of cortical activity by combining EEG and MEG with MRI cortical sur-


